GRANT Guide

Home » Grants » Comparative Effectiveness of Novel Pharmacologic and Evidence-Based Nonpharmacologic Treatments for Migraine Prevention — Cycle 2 2023 (USA)

Comparative Effectiveness of Novel Pharmacologic and Evidence-Based Nonpharmacologic Treatments for Migraine Prevention — Cycle 2 2023 (USA)

The Comparative Effectiveness of Novel Pharmacologic and Evidence-Based Nonpharmacologic Treatments for Migraine Prevention — Cycle 2 2023 research grant from the Patient-Centered Outcomes Research Institute (PCORI) supports rigorous, large-scale pragmatic trials that compare newly available pharmacologic and/or evidence-based nonpharmacologic treatments for the prevention of migraine. PCORI is particularly interested in studies that compare emerging pharmacological options such as CGRP antagonists to standard prophylactic therapy or to each other. PCORI is also interested in studies that examine the comparative effectiveness of evidence-based nonpharmacological options for migraine prevention. As appropriate, studies may include nonpharmacological interventions as standalone therapy or as an adjunct to pharmacological options. The grant provides up to 10 million USD in direct costs over 5 years.

Applications open on May 2, 2023. Letters of intent are due on May 31, 2023. Full invited applications are due on August 29, 2023.

Challenge: Clinical Trials

Sign in with your free account to see important eligibility criteria, including research location, citizenship, legal working rights and deadline/s.

Sign-up for the
scientifyRESEARCH
monthly research
funding newsletter

You can unsubscribe at any time.